Circulation

Vol. 152, Issue 16 Issue 16 2025
13
Articles

Articles in this Issue

A Crossroads in Cardiovascular Medicine: Progress and Barriers to Impact

Jessica A. Regan, Melissa H. Laitner, Victor J. Dzau Oct 21, 2025 pp. 1166-1173 10.1161/circulationaha.125.075592

During the past 75 years, advances in cardiovascular science and technology have significantly reduced morbidity and mortality. In 2012, Drs Nabel and Braunwald reviewed this progress in A...

Ivabradine in Patients Undergoing Noncardiac Surgery: A Randomized Controlled Trial

Jakub Fronczek, Bożena Seczyńska, Dominika Gryszówka et al. Oct 21, 2025 pp. 1126-1135 10.1161/circulationaha.125.076704

BACKGROUND: Perioperative beta blockade lowers heart rate and decreases the risk of myocardial infarction but increases the risk of hypotension, death, and stroke. Ivabradine, a se...

Response by Windfeld-Mathiasen et al to Letter Regarding Article, “Cardiovascular Disease in Anabolic Androgenic Steroid Users”

Josefine Windfeld-Mathiasen, Ida M. Heerfordt, Kim Peder Dalhoff et al. Oct 21, 2025 10.1161/circulationaha.125.075941

Clear as Mud: Determining the Stage of Prevention in Cardiovascular Disease

Ayeeshik Kole, Parag H. Joshi Oct 21, 2025 pp. 1123-1125 10.1161/circulationaha.125.074099

Response by Marcus to Letter Regarding Article, “Left Ventricular Entry to Reduce Brain Lesions During Catheter Ablation: A Randomized Trial”

Gregory M. Marcus Oct 21, 2025 10.1161/circulationaha.125.076073

PYGM Protects Against Myocardial Infarction by Enhancing Glycogenolysis and Facilitating Autophagic Flux

Jing Gan, Ruyi Zhao, Dong Zhen et al. Oct 21, 2025 pp. 1146-1165 10.1161/circulationaha.124.072312

BACKGROUND: PYGM (muscle glycogen phosphorylase), the rate-limiting enzyme in glycogenolysis, plays an indispensable role in maintaining cardiac energy metabolism. However, the role of PYG...

Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial

Torbjørn Omland, Siri Lagethon Heck, Espen Holte et al. Oct 21, 2025 pp. 1136-1145 10.1161/circulationaha.125.076616

BACKGROUND: Anthracycline- and trastuzumab-associated cardiotoxicity may lead to cardiac dysfunction and dose reduction or halt of potentially life-saving adjuvant cancer therapy. Whether...

Highlights From the <i>Circulation</i> Family of Journals

Oct 21, 2025 pp. 1174-1178 10.1161/circulationaha.125.077572

Letter by Liu and Huang Regarding Article, “Left Ventricular Entry to Reduce Brain Lesions During Catheter Ablation: A Randomized Trial”

Danyang Liu, Kun Huang Oct 21, 2025 10.1161/circulationaha.125.074546

Post–Myocardial Infarction Psychological Distress: A Scientific Statement From the American Heart Association

Glenn N. Levine, Robert M. Carney, Beth E. Cohen et al. Oct 21, 2025 10.1161/cir.0000000000001381

The importance of psychological distress in patients with cardiovascular disease is increasingly recognized as both a contributing factor to the development and progression of cardiovascular disease a...

Letter by Kornelius Regarding Article, “Cardiovascular Disease in Anabolic Androgenic Steroid Users”

Edy Kornelius Oct 21, 2025 10.1161/circulationaha.125.074873

Direct Therapeutic Modulation of RYR2 Activity by CMYA5

Fujian Lu, Zexuan Wu, Shaopeng Chi et al. Oct 21, 2025 pp. 1179-1182 10.1161/circulationaha.125.075402

Comparison of the Pooled Cohort and the PREVENT Cardiovascular Disease Risk Equations in the Veterans Health Administration

Sara J. King, Adam Furst, Jun Fan et al. Oct 21, 2025 pp. 1183-1185 10.1161/circulationaha.125.074224

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0009-7322
E-ISSN 1524-4539
Subject Health Sciences
Language English
View Full Journal Page